SAB Biotherapeutics (SABS) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

SABS SAB Biotherapeutics

Watchlist

2.9700
-0.0600-1.98%

Close Nov 26 16:00 ET

3.1700
+0.2000+6.73%

Post 17:48 ET

27.41MMarket Cap-471P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

SAB Biotherapeutics Third Quarter 2024 Earnings: US$1.12 Loss per Share (Vs US$0.97 Loss in 3Q 2023)
Yahoo FinanceNov 9 09:40 ET
Oppenheimer Maintains SAB Biotherapeutics(SABS.US) With Buy Rating, Maintains Target Price $12
Moomoo NewsNov 8 09:31 ET · Ratings
SAB Biotherapeutics Price Target Maintained With a $25.00/Share by Chardan Capital
Dow JonesNov 7 09:22 ET · Ratings
SAB Biotherapeutics Is Maintained at Buy by Chardan Capital
Dow JonesNov 7 09:22 ET · Ratings
H.C. Wainwright Maintains SAB Biotherapeutics(SABS.US) With Buy Rating, Maintains Target Price $6
Moomoo NewsNov 7 06:33 ET · Ratings
Promising Outlook for SAB Biotherapeutics' SAB-142 in Type 1 Diabetes Treatment Drives Buy Rating
TipRanksNov 7 06:16 ET · Ratings

Comments

Only Believe

Oct 16 13:35

$SAB Biotherapeutics (SABS.US)$
Keep Watch 👀

Clintzilla

Sep 20 13:22

$SAB Biotherapeutics (SABS.US)$ sneaky sneaky..

Jaguar8

Sep 9 06:02

NEWS

$SAB Biotherapeutics (SABS.US)$
SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting
SAB-142 has completed Phase 1 enrollment of all planned cohorts in healthy volunteers and is progressing to enroll patients with type 1 diabetes in the last cohort of the study.
Target dose of SAB-142 2.5mg/kg completed with no observation of serum sickness.
SAB-142 remains on track for a topline Phase 1 data readout by the end of the ye...

Trytosaveabit

May 21 06:16

News

$SAB Biotherapeutics (SABS.US)$ Reuters· just
FDA Provides Clearance to Ind Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics

Jaguar8

May 21 06:15

$SAB Biotherapeutics (SABS.US)$
NEWS
FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
SAB Biotherapeutics (Nasdaq: SABS) announced that the FDA has cleared its IND application for SAB-142, a type 1 diabetes therapy, to proceed to a Phase 1 clinical trial in the US.
SAB-142, a human anti-thymocyte immunoglobulin (hIgG), aims to delay the onset or progression of type 1 diabetes. The ongoing HUMAN trial will assess the safety, tolerability, pharmac...

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

SABS SAB Biotherapeutics

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target